Chronic Myeloid Leukemia

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

By

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

By

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Bosutinib May Be Effective As First-Line Therapy in Chronic-Phase Chronic Myeloid Leukemia

Bosutinib May Be Effective As First-Line Therapy in Chronic-Phase Chronic Myeloid Leukemia

By

Bosutinib is a dual Src/Abl tyrosine kinase inhibitor approved for newly diagnosed CP-CML and relapsed/refractory CML.

Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML

Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML

By

Data from a previous study supports treatment-free remission as a new treatment goal for patients with chronic-phase chronic myeloid leukemia.

Chronic Myeloid Leukemia and Gastrointestinal Cancer Risk—In the Clinic

Chronic Myeloid Leukemia and Gastrointestinal Cancer Risk—In the Clinic

By

There are some clinical data to support a potential for increased risk of additional solid organ malignancies in patients with CML.

Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

By

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

Pediatric CML: Life-Long Considerations With TKI Therapy

Pediatric CML: Life-Long Considerations With TKI Therapy

By

Because most patients with CML are adults, there are no established treatment guidelines and many clinicians apply adult guidelines to their pediatric patients.

Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

By

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

Nilotinib May Improve Rate of Deep Molecular Response in Chronic Myeloid Leukemia

Nilotinib May Improve Rate of Deep Molecular Response in Chronic Myeloid Leukemia

By

Previous studies have shown that first-line therapy with nilotinib, as well as switching to nilotinib after prolonged imatinib, may lead to higher rates of deep molecular response in chronic myeloid leukemia.

Deep Molecular Response May Allow TKI-therapy Discontinuation in Chronic Myeloid Leukemia

Deep Molecular Response May Allow TKI-therapy Discontinuation in Chronic Myeloid Leukemia

By

Targeted therapies among patients with chronic myeloid leukemia have improved over time, leading to patients achieving high rates of deep molecular response — a prerequisite criteria for tyrosine kinase inhibitor discontinuation.

Low-dose Dasatinib May Be Effective as Frontline Therapy in Chronic-phase Chronic Myeloid Leukemia

Low-dose Dasatinib May Be Effective as Frontline Therapy in Chronic-phase Chronic Myeloid Leukemia

By

Dasatinib 100 mg is currently approved for chronic myeloid leukemia but has been associated with high rates of adverse events.

The Hunt for Effective Anticancer Vaccines

The Hunt for Effective Anticancer Vaccines

By

Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.

Leukemia Treatment Regimens: Chronic Myeloid Leukemia (CML)

View detailed treatment regimens for chronic myeloid leukemia (CML), with detailed instructions about primary treatment and follow-up treatment.

HIV-Associated Cancers: A Paradigm Shift?

HIV-Associated Cancers: A Paradigm Shift?

By

Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

By

Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.

Phase 1 Trials: Therapy, Not Just Science

Phase 1 Trials: Therapy, Not Just Science

By

Phase 1 trials should be considered therapeutic options for some patients.

Immunotherapy and the Risk of Myocarditis

Immunotherapy and the Risk of Myocarditis

By

The risk should not discourage patients with cancer from taking these potentially life-extending therapies.

Identifying Treatment Failure in Patients With Chronic Myeloid Leukemia

Identifying Treatment Failure in Patients With Chronic Myeloid Leukemia

By

One study's results may be especially relevant for patients eligible for treatment discontinuation.

FDA Approves Nilotinib for Pediatric Patients With CML

FDA Approves Nilotinib for Pediatric Patients With CML

By

Patients one year or older are now eligible to receive the drug.

Can A Consortium of Hospitals Help To Reduce Drug Prices?

Can A Consortium of Hospitals Help To Reduce Drug Prices?

By

To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.

Patients with Chronic Myeloid Leukemia at Increased Risk of Secondary Cancers

Patients with Chronic Myeloid Leukemia at Increased Risk of Secondary Cancers

By

Recently published findings suggest that patients with CML, particularly men, have a 30% higher risk of developing secondary cancers; however the cause of this increased risk is unclear.

Molecular Response and Sokal Score Associated with Treatment-free Remission Duration in CML

Molecular Response and Sokal Score Associated with Treatment-free Remission Duration in CML

By

A subset of patients with chronic-phase CML in the ENESTfreedom study maintained treatment-free remission for at least 96 weeks after being treatment with frontline nilotinib.

Ivermectin Induces Apoptosis Through Mitochondrial Dysfunction in CML Cells

Ivermectin Induces Apoptosis Through Mitochondrial Dysfunction in CML Cells

By

A recent study sought to determine the effect of ivermectin against CML cells, whether ivermectin can sensitize cells to BCR-ABL TKIs, and its mechanism of action.

CML: Managing TKI-Related Toxicity To Yield the Best Outcomes

CML: Managing TKI-Related Toxicity To Yield the Best Outcomes

By

Preparing patients for treatment toxicity is important for ensuring that mild or moderate reactions do not undermine adherence.

Dasatinib: A Safe and Effective Option for Pediatric CML

Dasatinib: A Safe and Effective Option for Pediatric CML

By

Previous studies have shown that dasatinib may be an effective therapeutic alternative to imatinib.

Diagnosing Medicine's Intractable Gender Pay Gap

Diagnosing Medicine's Intractable Gender Pay Gap

By

The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.

Treatment-free remission of chronic myeloid leukemia possible after second-line nilotinib

1. Phase 2, open-label study results suggest that treatment-free remission (TFR) of chronic myeloid leukemia (CML) for ≥48 weeks can be reached by over half of patients who have reached deep molecular response (DMR) after ceasing second-line nilotinib treatment. 2. The authors suggest that for patients who do not reach sustained DMR with imatinib, changing []

Pediatric CML: Imatinib Effective in the Front Line

Pediatric CML: Imatinib Effective in the Front Line

By

Patients received imatinib 300 mg/m2, 400 mg/m2, and 500 mg/m2 for chronic phase, accelerated phase, and blast phase disease, respectively.

Managing Adverse Events in the Era of Immunotherapy

Managing Adverse Events in the Era of Immunotherapy

By

The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.

Healthful Lifestyles and Cancer: Much More Than A Single Behavior

Healthful Lifestyles and Cancer: Much More Than A Single Behavior

By

A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs